menu
    • menu
    [{"orgOrder":0,"company":"Purespring Therapeutics","sponsor":"SwanBio Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"AAV-based Gene Therapy","moa":"","graph1":"Neurology","graph2":"Discovery","graph3":"Purespring Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Purespring Therapeutics \/ SwanBio Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Purespring Therapeutics \/ SwanBio Therapeutics"},{"orgOrder":0,"company":"Purespring Therapeutics","sponsor":"Charles River Laboratories International","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"AAV-based Gene Therapy","moa":"","graph1":"Nephrology","graph2":"Preclinical","graph3":"Purespring Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Purespring Therapeutics \/ Charles River Laboratories International","highestDevelopmentStatusID":"4","companyTruncated":"Purespring Therapeutics \/ Charles River Laboratories International"},{"orgOrder":0,"company":"Purespring Therapeutics","sponsor":"Sofinnova Partners","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Series B Financing","leadProduct":"PS-002","moa":"","graph1":"Nephrology","graph2":"IND Enabling","graph3":"Purespring Therapeutics","amount2":0.11,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nephrology","amount2New":0.11,"dosageForm":"","sponsorNew":"Purespring Therapeutics \/ Sofinnova Partners","highestDevelopmentStatusID":"5","companyTruncated":"Purespring Therapeutics \/ Sofinnova Partners"}]

    Find Clinical Drug Pipeline Developments & Deals by Purespring Therapeutics

    Menu

    Purespring Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Purespring Therapeutics

    United Kingdom arrow
    DCAT Week
    Not Confirmed

    Purespring Therapeutics

    United Kingdom arrow
    DCAT Week
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : PS-002

    Therapeutic Area : Nephrology

    Study Phase : IND Enabling

    Sponsor : Sofinnova Partners

    Deal Size : $105.0 million

    Deal Type : Series B Financing

    DEALS_DEV arrow-down

    Purespring Therapeutics Raises $105M to Transform Kidney Disease Treatment

    Details : The proceeds will be used to support Purespring’s pipeline including the initiation of a Phase I/II clinical trial of PS-002 for IgAN, a chronic kidney disease primarily affecting young adults.

    Product Name : PS-002

    Product Type : Cell and Gene therapy

    Upfront Cash : Undisclosed

    October 09, 2024

    Lead Product(s) : PS-002

    Therapeutic Area : Nephrology

    Highest Development Status : IND Enabling

    Sponsor : Sofinnova Partners

    Deal Size : $105.0 million

    Deal Type : Series B Financing

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Purespring Therapeutics

    United Kingdom arrow
    DCAT Week
    Not Confirmed

    Purespring Therapeutics

    United Kingdom arrow
    DCAT Week
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : AAV-based Gene Therapy

    Therapeutic Area : Nephrology

    Study Phase : Preclinical

    Sponsor : Charles River Laboratories International

    Deal Size : Undisclosed

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    Charles River and Purespring Therapeutics Announce Gene Therapy Manufacturing Collaboration

    Details : Purespring’s Adeno Associated Virus (AAV) based gene therapy presents a lower-dose, local delivery approach which maximizes both safety and efficacy, as well as lowering the cost of goods.

    Product Name : Undisclosed

    Product Type : Cell and Gene therapy

    Upfront Cash : Undisclosed

    February 15, 2023

    Lead Product(s) : AAV-based Gene Therapy

    Therapeutic Area : Nephrology

    Highest Development Status : Preclinical

    Sponsor : Charles River Laboratories International

    Deal Size : Undisclosed

    Deal Type : Collaboration

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    Purespring Therapeutics

    United Kingdom arrow
    DCAT Week
    Not Confirmed

    Purespring Therapeutics

    United Kingdom arrow
    DCAT Week
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : AAV-based Gene Therapy

    Therapeutic Area : Neurology

    Study Phase : Discovery

    Sponsor : SwanBio Therapeutics

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    DEALS_DEV arrow-down

    Purespring Therapeutics And SwanBio Therapeutics Announce Licensing Agreement for Use of FunSel Screening Plat...

    Details : Under the terms of the agreement, SwanBio will license the FunSel screening platform from Purespring to explore new targets for early-stage pipeline programs. SwanBio will have an option to develop any targets identified and to own and commercialise any ...

    Product Name : Undisclosed

    Product Type : Cell and Gene therapy

    Upfront Cash : Undisclosed

    July 18, 2022

    Lead Product(s) : AAV-based Gene Therapy

    Therapeutic Area : Neurology

    Highest Development Status : Discovery

    Sponsor : SwanBio Therapeutics

    Deal Size : Undisclosed

    Deal Type : Licensing Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth